Avicanna Inc
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with vari… Read more
Avicanna Inc (AVCNF) - Total Assets
Latest total assets as of September 2025: $21.17 Million USD
Based on the latest financial reports, Avicanna Inc (AVCNF) holds total assets worth $21.17 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Avicanna Inc - Total Assets Trend (2016–2024)
This chart illustrates how Avicanna Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Avicanna Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Avicanna Inc's total assets of $21.17 Million consist of 38.0% current assets and 62.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 2.2% |
| Accounts Receivable | $2.95 Million | 14.7% |
| Inventory | $3.97 Million | 19.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $868.92K | 4.3% |
| Goodwill | $334.00K | 1.7% |
Asset Composition Trend (2016–2024)
This chart illustrates how Avicanna Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Avicanna Inc's current assets represent 38.0% of total assets in 2024, a decrease from 99.9% in 2016.
- Cash Position: Cash and equivalents constituted 2.2% of total assets in 2024, down from 98.3% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 19.8% of total assets.
Avicanna Inc Competitors by Total Assets
Key competitors of Avicanna Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Avicanna Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Avicanna Inc generates 1.27x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Avicanna Inc is currently not profitable relative to its asset base.
Avicanna Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.90 | 0.83 | 0.53 |
| Quick Ratio | 0.38 | 0.43 | 0.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-833.13K | $ -1.62 Million | $ -6.05 Million |
Avicanna Inc - Advanced Valuation Insights
This section examines the relationship between Avicanna Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.59 |
| Latest Market Cap to Assets Ratio | 0.81 |
| Asset Growth Rate (YoY) | -8.4% |
| Total Assets | $20.12 Million |
| Market Capitalization | $16.21 Million USD |
Valuation Analysis
Near Book Valuation: The market values Avicanna Inc's assets close to their book value ( 0.81x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Avicanna Inc's assets decreased by 8.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Avicanna Inc (2016–2024)
The table below shows the annual total assets of Avicanna Inc from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $20.12 Million | -8.44% |
| 2023-12-31 | $21.97 Million | +24.70% |
| 2022-12-31 | $17.62 Million | -21.00% |
| 2021-12-31 | $22.30 Million | -26.04% |
| 2020-12-31 | $30.16 Million | -33.23% |
| 2019-12-31 | $45.16 Million | +60.27% |
| 2018-12-31 | $28.18 Million | +1230.88% |
| 2017-12-31 | $2.12 Million | +2176.82% |
| 2016-12-31 | $93.00K | -- |